Improvement in childhood cancer survival in Lithuania over three decades.
Lithuania
childhood cancer
survival
Journal
Acta medica Lituanica
ISSN: 1392-0138
Titre abrégé: Acta Med Litu
Pays: Lithuania
ID NLM: 9442465
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
25
6
2020
Statut:
ppublish
Résumé
Population-based EUROCARE-5 studies demonstrated that childhood cancer survival rates in Lithuania were 10-20% lower than the European mean. We aimed to analyse the change in the outcome of treatment of paediatric malignancies in Lithuania over 30 years. A single-centre retrospective analysis of children below 18 years of age treated for cancer at Vilnius University Hospital Santaros Klinikos between 1982 and 2011 was carried out. The minimal requirement of 5-year follow-up after diagnosis was specified for survival estimation. The vital status was assessed using data from the population-based Lithuanian Cancer Registry. To evaluate changes over time, the entire cohort was split into three groups according to the time of diagnosis: 1982-1991, 1992-2001, and 2002-2011. A total of 1268 children met the inclusion criteria. The shortest median follow-up was 8.9 (IQR 6.4-11.5) years for patients treated in the third decade. The 5-year overall survival of the entire cohort increased from 37.3% (95% CI 30.2-44.3) in 1982-1991 to 70.7% (95% CI 66.4-74.1) in 2002-2011 ( Significant progress in the cure rate of children treated for cancer at our institution was observed over 30 years. Collaborative national and international clinical and research efforts are crucial to ensure further advances in care and cure. Santrauka
Sections du résumé
BACKGROUND
BACKGROUND
Population-based EUROCARE-5 studies demonstrated that childhood cancer survival rates in Lithuania were 10-20% lower than the European mean. We aimed to analyse the change in the outcome of treatment of paediatric malignancies in Lithuania over 30 years.
METHODS
METHODS
A single-centre retrospective analysis of children below 18 years of age treated for cancer at Vilnius University Hospital Santaros Klinikos between 1982 and 2011 was carried out. The minimal requirement of 5-year follow-up after diagnosis was specified for survival estimation. The vital status was assessed using data from the population-based Lithuanian Cancer Registry. To evaluate changes over time, the entire cohort was split into three groups according to the time of diagnosis: 1982-1991, 1992-2001, and 2002-2011.
RESULTS
RESULTS
A total of 1268 children met the inclusion criteria. The shortest median follow-up was 8.9 (IQR 6.4-11.5) years for patients treated in the third decade. The 5-year overall survival of the entire cohort increased from 37.3% (95% CI 30.2-44.3) in 1982-1991 to 70.7% (95% CI 66.4-74.1) in 2002-2011 (
CONCLUSIONS
CONCLUSIONS
Significant progress in the cure rate of children treated for cancer at our institution was observed over 30 years. Collaborative national and international clinical and research efforts are crucial to ensure further advances in care and cure.
VAIKŲ VĖŽIO IŠEIČIŲ PAGERĖJIMAS LIETUVOJE PER 30 METŲ
UNASSIGNED
Santrauka
Autres résumés
Type: Publisher
(lit)
Santrauka
Identifiants
pubmed: 32577090
doi: 10.6001/actamedica.v27i1.4260
pmc: PMC7305808
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-9Informations de copyright
© Lietuvos mokslų akademija, 2020.
Références
Medicina (Kaunas). 2014;50(1):28-36
pubmed: 25060202
Eur J Cancer. 2017 Sep;82:137-148
pubmed: 28689091
Medicina (Kaunas). 2005;41(12):1026-34
pubmed: 16401959
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Acta Med Litu. 2017;24(2):128-137
pubmed: 28845131
Eur J Pediatr. 2017 Oct;176(10):1329-1337
pubmed: 28812191
Acta Med Litu. 2017;24(4):199-208
pubmed: 29487483
Lancet Oncol. 2014 Jan;15(1):35-47
pubmed: 24314616
Acta Med Litu. 2019;26(2):125-133
pubmed: 31632187
Haematologica. 2012 May;97(5):635
pubmed: 22556350
Klin Padiatr. 2016 Nov;228(6-07):286-293
pubmed: 27846658
Sci Rep. 2019 Nov 28;9(1):17867
pubmed: 31780760
Eur J Cancer Prev. 2017 Sep;26 Joining forces for better cancer registration in Europe:S147-S152
pubmed: 28604420
J Natl Cancer Inst. 2020 Mar 03;:
pubmed: 32123906
Lancet Haematol. 2017 May;4(5):e202-e217
pubmed: 28411119
Pediatr Blood Cancer. 2014 Sep;61(9):1551-7
pubmed: 24706509
Ecancermedicalscience. 2011;5:210
pubmed: 22276053
Front Public Health. 2019 Apr 18;7:84
pubmed: 31106186
J Clin Oncol. 2015 Sep 20;33(27):2963-74
pubmed: 26304908
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Semin Radiat Oncol. 2010 Jan;20(1):67-78
pubmed: 19959033
Science. 2019 Mar 15;363(6432):1182-1186
pubmed: 30872518